Pizotifen
Structural formula | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
General | ||||||||||||||||||||||
Surname | Pizotifen | |||||||||||||||||||||
other names | ||||||||||||||||||||||
Molecular formula | C 19 H 21 NS | |||||||||||||||||||||
External identifiers / databases | ||||||||||||||||||||||
|
||||||||||||||||||||||
Drug information | ||||||||||||||||||||||
ATC code | ||||||||||||||||||||||
Drug class |
Migraine drugs |
|||||||||||||||||||||
Mechanism of action | ||||||||||||||||||||||
properties | ||||||||||||||||||||||
Molar mass | 295.44 g · mol -1 | |||||||||||||||||||||
Melting point |
197-198 ° C (dec); 185-186 ° C (malate, decomp.) |
|||||||||||||||||||||
pK s value |
7.0 |
|||||||||||||||||||||
safety instructions | ||||||||||||||||||||||
|
||||||||||||||||||||||
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions . |
The drug pizotifen was previously used for interval treatment of migraines and for migraine prophylaxis . It was also used against a lack of appetite . The malate is used .
Pizotifen was patented by Sandoz in 1966 and was on the market under the trade names Mosegor ® and Sandomigran ® .
Pharmacological properties
The drug is an antagonist of serotonin receptors and also has an antihistamine effect.
literature
- Ernst Mutschler: drug effects . 7th edition. Wissenschaftliche Verlagsgesellschaft, Stuttgart 1996, pp. 224–225 u. 393-394, ISBN 3-8047-1377-7 .
Individual evidence
- ↑ a b c d e Entry on Pizotifen. In: Römpp Online . Georg Thieme Verlag, accessed on July 24, 2019.
- ↑ harmonized classification for this substance . A labeling of pizotifen in the Classification and Labeling Inventory of the European Chemicals Agency (ECHA), which was accessed on July 11, 2020, is reproduced from a self-classification by distributors . There is not yet a